A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease

Seminars in Arthritis and Rheumatism

Volumn 46, Issue 5, 2017, Pages 625-631

  Daoussis, Dimitrios ^a   Melissaropoulos, Konstantinos ^a   Sakellaropoulos, Georgios ^e   Antonopoulos, Ioannis ^a   Markatseli, Theodora E ^b   Simopoulou, Theodora ^c   Georgiou, Panagiotis ^d   Andonopoulos, Andrew P ^a   Drosos, Alexandros A ^b   Sakkas, Lazaros ^c   Liossis, Stamatis Nick ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^d Department of Urology   (Greece)

^e UNIVERSITY OF PATRAS   (Greece)

Author keywords

B cells; Fibrosis; Interstitial lung disease; Rituximab; Scleroderma; Systemic sclerosis

Indexed keywords

AZATHIOPRINE; METHOTREXATE; MYCOPHENOLATE MOFETIL; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PROSTATE CANCER; RESPIRATORY TRACT INFECTION; SKIN FIBROSIS; SKINFOLD; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; AGED; B LYMPHOCYTE; CASE CONTROL STUDY; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG; LYMPHOCYTE DEPLETION; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SKIN; TIME FACTOR;

ADULT; AGED; B-LYMPHOCYTES; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LUNG; LUNG DISEASES, INTERSTITIAL; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RITUXIMAB; SCLERODERMA, SYSTEMIC; SKIN; TIME FACTORS;

EID: 85006271564     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2016.10.003     Document Type: Article

References (45)

1. [1] Elhai, M., Meune, C., Avouac, J., Kahan, A., Allanore, Y., Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 51 (2012), 1017–1026.
2. [2] Sakkas, L.I., Chikanza, I.C., Platsoucas, C.D., Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2 (2006), 679–685.
3. [3] Bhattacharyya, S., Wei, J., Varga, J., Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 8 (2012), 42–54.
4. [4] Trojanowska, M., Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol 6 (2010), 453–460.
5. [5] Gabrielli, A., Avvedimento, E.V., Krieg, T., Scleroderma. N Engl J Med 360 (2009), 1989–2003.
6. [6] Varga, J., Abraham, D., Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117 (2007), 557–567.
7. [7] Tashkin, D.P., Elashoff, R., Clements, P.J., Goldin, J., Roth, M.D., Furst, D.E., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:25 (2006), 2655–2666.
8. [8] Tashkin, D.P., Elashoff, R., Clements, P.J., Roth, M.D., Furst, D.E., Silver, R.M., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176 (2007), 1026–1034.
9. [9] Liossis, S.N., Bounas, A., Andonopoulos, A.P., Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 45 (2006), 1005–1008.
10. [10] Nihtyanova, S.I., Brough, G.M., Black, C.M., Denton, C.P., Mycophenolate mofetil in diffuse cutaneous systemic sclerosis—a retrospective analysis. Rheumatology (Oxford) 46 (2007), 442–445.
11. [11] van Laar, J.M., Farge, D., Sont, J.K., Naraghi, K., Marjanovic, Z., Larghero, J., et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. J Am Med Assoc 311 (2014), 2490–2498.
12. [12] Bosello, S., De Santis, M., Lama, G., Spano, C., Angelucci, C., Tolusso, B., et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther, 12, 2010, R54.
13. [13] Smith, V., Van Praet, J.T., Vandooren, B., Van der, C.B., Naeyaert, J.M., Decuman, S., et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 69 (2010), 193–197.
14. [14] Smith, V., Piette, Y., van Praet, J.T., Decuman, S., Deschepper, E., Elewaut, D., et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 40:1 (2013), 52–57.
15. [15] Daoussis, D., Liossis, S.N., Tsamandas, A.C., Kalogeropoulou, C., Paliogianni, F., Sirinian, C., et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 30:2 Suppl. 71 (2012), S17–S22.
16. [16] Francois, A., Chatelus, E., Wachsmann, D., Sibilia, J., Bahram, S., Alsaleh, G., et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther, 15, 2013, R168.
17. [17] Daoussis, D., Liossis, S.N., B cells tell scleroderma fibroblasts to produce collagen. Arthritis Res Ther, 15, 2013, 125.
18. [18] Daoussis, D., Liossis, S.N., Yiannopoulos, G., Andonopoulos, A.P., B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol, 2011, 2011, 214013.
19. [19] Daoussis, D., Liossis, S.N., Tsamandas, A.C., Kalogeropoulou, C., Kazantzi, A., Korfiatis, P., et al. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum 40 (2010), 127–136.
20. [20] Hasegawa, M., B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis. J Dermatol 37 (2010), 3–10.
21. [21] Hasegawa, M., Hamaguchi, Y., Yanaba, K., Bouaziz, J.D., Uchida, J., Fujimoto, M., et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169 (2006), 954–966.
22. [22] Hasegawa, M., Fujimoto, M., Takehara, K., Sato, S., Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J Dermatol Sci 39 (2005), 1–7.
23. [23] Asano, N., Fujimoto, M., Yazawa, N., Shirasawa, S., Hasegawa, M., Okochi, H., et al. B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 165 (2004), 641–650.
24. [24] Sato, S., Fujimoto, M., Hasegawa, M., Takehara, K., Tedder, T.F., Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 41 (2004), 1123–1133.
25. [25] Saito, E., Fujimoto, M., Hasegawa, M., Komura, K., Hamaguchi, Y., Kaburagi, Y., et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 109 (2002), 1453–1462.
26. [26] Fraticelli, P., De Vita, S., Franzolini, N., Svegliati, S., Scott, C.A., Tonnini, C., et al. Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab. Clin Exp Rheumatol 33:4 Suppl. 91 (2015), S160–S167.
27. [27] Daoussis, D., Liossis, S.N., Tsamandas, A.C., Kalogeropoulou, C., Kazantzi, A., Sirinian, C., et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 49 (2010), 271–280.
28. [28] Steen, V.D., Conte, C., Owens, G.R., Medsger, T.A. Jr, Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37 (1994), 1283–1289.
29. [29] Bosello, S.L., De Luca, G., Rucco, M., Berardi, G., Falcione, M., Danza, F.M., et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum 44 (2015), 428–436.
30. [30] Giuggioli, D., Lumetti, F., Colaci, M., Fallahi, P., Antonelli, A., Ferri, C., Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev 14 (2015), 1072–1078.
31. [31] Haroon, M., McLaughlin, P., Henry, M., Harney, S., Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids. Ther Adv Respir Dis 5 (2011), 299–304.
32. [32] Keir, G.J., Maher, T.M., Ming, D., Abdullah, R., de Lauretis, A., Wickremasinghe, M., et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 19 (2014), 353–359.
33. [33] Lafyatis, R., Kissin, E., York, M., Farina, G., Viger, K., Fritzler, M.J., et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60 (2009), 578–583.
34. [34] McGonagle, D., Tan, A.L., Madden, J., Rawstron, A.C., Rehman, A., Emery, P., et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 47 (2008), 552–553.
35. [35] Moazedi-Fuerst, F.C., Kielhauser, S.M., Brickmann, K., Hermann, J., Lutfi, A., Meilinger, M., et al. Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen. Scand J Rheumatol 43 (2014), 257–258.
36. [36] Smith, V., Pizzorni, C., Riccieri, V., Decuman, S., Brusselle, G., DE Pauw, M., et al. Stabilization of microcirculation in patients with early systemic sclerosis with diffuse skin involvement following rituximab treatment: an open-label study. J Rheumatol 43 (2016), 995–996.
37. [37] Jordan, S., Distler, J.H., Maurer, B., Huscher, D., van Laar, J.M., Allanore, Y., et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 74 (2015), 1188–1194.
38. [38] Preliminary Criteria for the Classification of Systemic Sclerosis (Scleroderma), Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23 (1980), 581–590.
39. [39] van den, H.F., Khanna, D., Fransen, J., Johnson, S.R., Baron, M., Tyndall, A., et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65 (2013), 2737–2747.
40. [40] Mavropoulos, A., Simopoulou, T., Varna, A., Liaskos, C., Katsiari, C.G., Bogdanos, D.P., et al. Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis. Arthritis Rheumatol 68 (2016), 494–504.
41. [41] Sato, S., Fujimoto, M., Hasegawa, M., Takehara, K., Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 50 (2004), 1918–1927.
42. [42] Whitfield, M.L., Finlay, D.R., Murray, J.I., Troyanskaya, O.G., Chi, J.T., Pergamenschikov, A., et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 100 (2003), 12319–12324.
43. [43] Lafyatis, R., O'Hara, C., Feghali-Bostwick, C.A., Matteson, E., B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 56 (2007), 3167–3168.
44. [44] McQueen, F.M., Solanki, K., Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?. Rheumatology (Oxford) 54 (2015), 757–767.
45. [45] Wu, M., Mohan, C., B-cells in systemic sclerosis: emerging evidence from genetics to phenotypes. Curr Opin Rheumatol 27 (2015), 537–541.